Goldman Sachs Put 2700 TDXP 21.03.../ DE000GJ3MP31 /
13.11.2024 11:24:14 | Изменение+0.020 | Бид22:00:26 | Предложение22:00:26 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
0.230EUR | +9.52% | - Величина цены спроса: - |
- Величина цены предложения: - |
TECDAX | 2,700.00 EUR | 21.03.2025 | Put |
GlobeNewswire
22.07
MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire
12.06.2018
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
13.12.2016
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
06.12.2016
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
06.12.2016
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
28.11.2016
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
17.11.2016
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
15.11.2016
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
08.11.2016
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
03.11.2016
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
02.11.2016
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
20.10.2016
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
17.10.2016
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire
01.10.2016
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire
01.10.2016
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire
29.09.2016
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница